Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research highlights Bristol Myers Squibb (BMY) as a value stock to watch, assigning it a Zacks Rank of #3 (Hold) with a VGM Score of A and a Value Style Score of A. BMY's forward P/E ratio stands at 6.8, and the consensus earnings estimate for fiscal year 2025 has increased by $0.14 to $6.89 per share following upward revisions from 12 analysts in the last 60 days, suggesting potential upside despite generic competition for some of its legacy drugs.

Analysis

Bristol Myers Squibb (BMY) presents a compelling case for value-oriented investors according to Zacks Investment Research, despite its current Zacks Rank of #3 (Hold). The company's strong appeal is underscored by 'A' grades in both its Value and overall VGM Style Scores, a reflection of attractive valuation metrics such as a forward P/E ratio of 6.8. This valuation context is significant as BMY navigates generic competition for key legacy drugs like Revlimid, Pomalyst, Sprycel, and Abraxane by actively refreshing its portfolio with newer treatments including the blockbuster Opdivo and emerging drugs Reblozyl, Breyanzi, Camzyos, and Opdualag, alongside maintaining a diversified revenue stream from its immunology (Orencia) and cardiovascular (Eliquis) segments. A notable positive development is the upward revision in fiscal 2025 earnings expectations: 12 analysts have increased their estimates over the past 60 days, pushing the Zacks Consensus Estimate up by $0.14 to $6.89 per share. Coupled with a historical average earnings surprise of 20.2%, these factors suggest underlying financial health and potential for outperformance, aligning with Zacks' guidance that #3 ranked stocks with A or B style scores can offer upside potential.

Key Decisions for Investors

• Investors may consider BMY as a potential value opportunity, given its 'A' rated Value and VGM Style Scores and a low forward P/E of 6.8, even with a neutral Zacks #3 (Hold) rank.
• Careful monitoring of BMY's pipeline success, particularly the sales trajectory of newer drugs like Reblozyl, Breyanzi, Camzyos, and Opdualag, is crucial in assessing its ability to offset the impact of generic erosion on legacy products.
• The consensus upward revision of FY2025 earnings estimates to $6.89 per share, driven by 12 analysts, alongside a strong 20.2% average earnings surprise, should be weighed as indicators of improving fundamental outlook that might not be fully captured by the current Hold rating.